The interest in IL-28B is sufficiently recent that completed HCV studies with DAA’s have only haphazard data, at best, on the effect of the gene variants.
Also if you were a CC and had an 80% chance of SVR would they even use a DAA?
I do not understand your question—can you rephrase it?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.